| ［1］ |
Hoi A, Igel T, Mok CC, et al. Systemic lupus erythematosus［J］. Lancet, 2024,403（10441）:2326⁃2338. doi: 10.1016/S0140⁃6736（24）00398⁃2.
|
| ［2］ |
Ramírez⁃Valle F, Maranville JC, Roy S, et al. Sequential immunotherapy: towards cures for autoimmunity［J］. Nat Rev Drug Discov, 2024,23（7）:501⁃524. doi: 10.1038/s41573⁃024⁃00959⁃8.
|
| ［3］ |
Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party （ADWP） of the European Society for Blood and Marrow Transplantation （EBMT）［J］. Bone Marrow Transplant, 2022,57（7）:1055⁃1062. doi: 10.1038/s41409⁃022⁃01702⁃w.
|
| ［4］ |
Alchi B, Jayne D, Labopin M, et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry［J］. Lupus, 2013,22（3）:245⁃253. doi: 10.1177/0961203 312470729.
|
| ［5］ |
Daikeler T, Labopin M, Di Gioia M, et al. Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party［J］. Blood, 2011,118（6）:1693⁃1698. doi: 10.1182/blood⁃2011⁃02⁃336156.
|
| ［6］ |
中华医学会风湿病学分会, 中国医院协会临床新技术应用专业委员会. 异体间充质干细胞治疗系统性红斑狼疮专家共识［J］. 中华风湿病学杂志, 2022,26（1）:1⁃8. doi: 10.3760/cma.j.cn141217⁃20210923⁃00381.
|
| ［7］ |
Xia Y, Ye H, Li K, et al. Efficacy of mesenchymal stem cell therapy on lupus nephritis and renal function in systemic lupus erythematosus: a meta⁃analysis［J］. Clin Invest Med, 2023,46（1）:E24⁃35. doi: 10.25011/cim.v46i1.39561.
|
| ［8］ |
Xu J, Chen J, Li W, et al. Additive therapeutic effects of mesenchymal stem cells and IL⁃37 for systemic lupus erythematosus［J］. J Am Soc Nephrol, 2020,31（1）:54⁃65. doi: 10.1681/ASN.2019050545.
|
| ［9］ |
Zhu HF, Kong B, Nie M, et al. ECM⁃inspired peptide dendrimer microgels with human MSCs encapsulation for systemic lupus erythematosus treatment［J］. Nano Today, 2022,43:101454. doi: 10.1016/j.nantod.2022.101454.
|
| ［10］ |
Zhang M, Johnson⁃Stephenson TK, Wang W, et al. Mesenchymal stem cell⁃derived exosome⁃educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL⁃17+ regulatory T cell［J］. Stem Cell Res Ther, 2022,13（1）:484. doi: 10.1186/s13287⁃022⁃03174⁃7.
|
| ［11］ |
Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19⁃targeted CAR T cells is a highly effective treatment for murine lupus［J］. Sci Transl Med, 2019,11（482）:eaav1648. doi: 10.1126/scitranslmed.aav1648.
|
| ［12］ |
Jin X, Xu Q, Pu C, et al. Therapeutic efficacy of anti⁃CD19 CAR⁃T cells in a mouse model of systemic lupus erythematosus［J］. Cell Mol Immunol, 2021,18（8）:1896⁃1903. doi: 10.1038/s41423⁃020⁃0472⁃1.
|
| ［13］ |
Mougiakakos D, Krönke G, Völkl S, et al. CD19⁃targeted CAR T cells in refractory systemic lupus erythematosus［J］. N Engl J Med, 2021,385（6）:567⁃569. doi: 10.1056/NEJMc2107725.
|
| ［14］ |
Mackensen A, Müller F, Mougiakakos D, et al. Anti⁃CD19 CAR T cell therapy for refractory systemic lupus erythematosus［J］. Nat Med, 2022,28（10）:2124⁃2132. doi: 10.1038/s41591⁃022⁃02017⁃5.
|
| ［15］ |
Müller F, Taubmann J, Bucci L, et al. CD19 CAR T⁃cell therapy in autoimmune disease ⁃ a case series with follow⁃up［J］. N Engl J Med, 2024,390（8）:687⁃700. doi: 10.1056/NEJ Moa2308917.
|
| ［16］ |
Krickau T, Naumann⁃Bartsch N, Aigner M, et al. CAR T⁃cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis［J］. Lancet, 2024,403（10437）:1627⁃1630. doi: 10.1016/S0140⁃6736（24）00424⁃0.
|
| ［17］ |
Wang W, He S, Zhang W, et al. BCMA⁃CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open⁃label clinical trial［J］. Ann Rheum Dis, 2024,83（10）:1304⁃1314. doi: 10.1136/ard⁃2024⁃225785.
|
| ［18］ |
Feng JJ, Hu YX, Chang AH, et al. CD19/BCMA CAR⁃T cell therapy for refractory systemic lupus erythematosus⁃safety and preliminary efficacy data from a phase I clinical study［J］. Blood, 2023, 142 （Suppl 1）: 4835. doi: 10.1182/blood⁃2023⁃186669.
|
| ［19］ |
Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T⁃cell therapy［J］. N Engl J Med, 2024,390（7）:584⁃586. doi: 10.1056/NEJMp2400209.
|
| ［20］ |
Wang X, Wu X, Tan B, et al. Allogeneic CD19⁃targeted CAR⁃T therapy in patients with severe myositis and systemic sclerosis［J］. Cell, 2024,187（18）:4890⁃4904.doi: 10.1016/j.cell. 2024. 06.027.
|
| ［21］ |
Mehta A, Farooq U, Chen A, et al. Interim phase Ⅰ clinical data of FT819⁃101, a study of the first⁃ever, off⁃the⁃shelf, iPSC⁃derived TCR⁃less CD19 CAR T⁃cell therapy for patients with relapsed/refractory B⁃cell malignancies［J］. Blood, 2022,140 （Suppl 1）:4577⁃4578. doi: 10.1182/blood⁃2022⁃167194.
|
| ［22］ |
Rozenbaum M, Meir A, Aharony Y, et al. Gamma⁃delta CAR⁃T cells show CAR⁃directed and independent activity against leukemia［J］. Front Immunol, 2020,11:1347. doi: 10.3389/fimmu.2020.01347.
|
| ［23］ |
Granit V, Benatar M, Kurtoglu M, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T⁃cell therapy in myasthenia gravis （MG⁃001）: a prospective, multicentre, open⁃label, non⁃randomised phase 1b/2a study［J］. Lancet Neurol, 2023,22（7）:578⁃590. doi: 10.1016/S1474⁃4422（23）00194⁃1.
|
| ［24］ |
O'Brien S, Nastoupil LJ, Essell J, et al. A first⁃in⁃human phase 1, multicenter, open⁃label study of CB⁃010, a next⁃generation CRISPR⁃edited allogeneic anti⁃CD19 CAR⁃T cell therapy with a PD⁃1 knockout, in patients with relapsed/refractory B cell non⁃Hodgkin lymphoma （ANTLER study）［J］. Blood, 2022,140 （Suppl 1）:9457⁃9458. doi: 10.1182/blood⁃2022⁃168128.
|
| ［25］ |
Mullard A. In vivo CAR T cells move into clinical trials［J］. Nat Rev Drug Discov, 2024,23（10）:727⁃730. doi: 10.1038/d41573⁃024⁃00150⁃z.
|
| ［26］ |
Sin WX, Jagannathan NS, Teo D, et al. A high⁃density microfluidic bioreactor for the automated manufacturing of CAR T cells［J］. Nat Biomed Eng, 2024,8（12）:1571⁃1591. doi: 10. 1038/s41551⁃024⁃01219⁃1.
|
| ［27］ |
Khanal R, Saultz JN, Farooq U, et al. Trial in progress: AB⁃101, an allogeneic, non⁃engineered, cord blood⁃derived natural killer （NK） cell therapy, as monotherapy or in combination with rituximab in patients with relapsed or refractory non⁃Hodgkin lymphoma［J］. Blood, 2022,140（Suppl 1）:12742⁃12743. doi: 10. 1182/blood⁃2022⁃159282.
|
| ［28］ |
Reighard SD, Cranert SA, Rangel KM, et al. Therapeutic targeting of follicular T cells with chimeric antigen receptor⁃expressing natural killer cells［J］. Cell Rep Med, 2020,1（1）:100003［pii］. doi: 10.1016/j.xcrm.2020.100003.
|
| ［29］ |
Meng H, Sun X, Song Y, et al. La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease［J］. Clin Immunol, 2018,192:40⁃49. doi: 10.1016/j.clim.2018.04.006.
|
| ［30］ |
Dall'Era M, Pauli ML, Remedios K, et al. Adoptive Treg cell therapy in a patient with systemic lupus erythematosus［J］. Arthritis Rheumatol, 2019,71（3）:431⁃440. doi: 10.1002/art. 40737.
|
| ［31］ |
Doglio M, Ugolini A, Bercher⁃Brayer C, et al. Regulatory T cells expressing CD19⁃targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus［J］. Nat Commun, 2024,15（1）:2542. doi: 10.1038/s41467⁃024⁃46448⁃9.
|
| ［32］ |
Eggenhuizen PJ, Cheong R, Lo C, et al. Smith⁃specific regulatory T cells halt the progression of lupus nephritis［J］. Nat Commun, 2024,15（1）:899. doi: 10.1038/s41467⁃024⁃45056⁃x.
|
